Prevention and treatment of acute myeloid leukemia relapse after hematopoietic stem cell transplantation: the state of the art and future perspectives

S Leotta, A Condorelli, R Sciortino, GA Milone… - Journal of Clinical …, 2022 - mdpi.com
Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid
leukemia (AML) represents the only curative option. Progress has been made in the last two …

[HTML][HTML] Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment

Y Serroukh, J Hébert, L Busque, F Mercier, CE Rudd… - Blood Reviews, 2023 - Elsevier
Acute myeloid leukemia (AML) is a cancer that originates from the bone marrow (BM). Under
physiological conditions, the bone marrow supports the homeostasis of immune cells and …

Immune landscape after allo-HSCT: TIGIT-and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse

V Gournay, N Vallet, V Peux, K Vera… - Blood, The Journal …, 2022 - ashpublications.org
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective
treatment for selected patients with acute myeloid leukemia (AML) and relies on a “graft …

Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter …

L Yang, X Lai, T Yang, Y Lu, L Liu, J Shi… - Bone Marrow …, 2024 - nature.com
Donor lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation
(allo-HSCT) has been widely used in preventing post-transplant relapse. We conducted this …

Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML relapse

I Odak, R Sikora, L Riemann, LM Bayir, M Beck… - Frontiers in …, 2022 - frontiersin.org
Identification of immune phenotypes linked to durable graft-versus-leukemia (GVL) response
following donor lymphocyte infusions (DLI) is of high clinical relevance. In this prospective …

The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia

E Maffini, M Ursi, F Barbato, M Dicataldo… - Frontiers in …, 2022 - frontiersin.org
Disease relapse represents by far the most frequent cause of hematopoietic cell
transplantation (HCT) failure. Patients with acute leukemia suffering relapse after HCT have …

Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor …

EAS Koster, EF Bonneville, PA Borne… - Frontiers in …, 2023 - frontiersin.org
Alloreactive donor-derived T-cells play a pivotal role in alloimmune responses after
allogeneic hematopoietic stem cell transplantation (alloSCT); both in the relapse-preventing …

Healthy-like CD4+ Regulatory and CD4+ Conventional T-Cell Receptor Repertoires Predict Protection from GVHD Following Donor Lymphocyte Infusion

J Schneider, L Kuhlmann, Y Xiao, S Raha… - International Journal of …, 2022 - mdpi.com
Donor lymphocyte infusion (DLI) can (re-) induce durable remission in relapsing patients
after allogeneic hematopoietic stem-cell transplantation (alloHSCT). However, DLI harbors …

T-cell receptor sequencing reveals selected donor-reactive CD8+ T cell clones resist antithymocyte globulin depletion after kidney transplantation

M Ningoo, P Cruz-Encarnación, C Khilnani… - American Journal of …, 2024 - Elsevier
High frequencies of donor-reactive memory T cells in the periphery of transplant candidates
prior to transplantation are linked to the development of posttransplant acute rejection …

[PDF][PDF] Joint models quantif associations bet een immune cell kinetics and allo-immunological e ents after allogeneic stem cell transplantation and subsequent donor l …

LC Wreede - 2023 - scholarlypublications …
The curative potential of allogeneic stem cell transplantation (alloSCT) in the treatment of
hematological malignancies depends on the introduction of donor-derived alloreactive T …